

Resource Summary Report

Generated by PRECISE-TBI on Aug 1, 2026

Statistical Analysis System

RRID:SCR_008567

Type: Tool

Proper Citation

Statistical Analysis System (RRID:SCR_008567)

Resource Information

URL: <http://www.sas.com>

Proper Citation: Statistical Analysis System (RRID:SCR_008567)

Description: Software platform to explore, analyze and visualize data. SAS 9.4 is part of SAS Platform. Standardized data governance and management from statistical software company SAS.

Abbreviations: SAS

Synonyms: Statistical Analysis System, SAS Intelligence Platform, SAS 9.3, SAS 9.4

Resource Type: software resource, software application, data analytics software, data management software

Keywords: Explore, analyze, visualize, data, standardized, management, statistics

Availability: Restircted

Resource Name: Statistical Analysis System

Resource ID: SCR_008567

Alternate IDs: nif-0000-31484

Alternate URLs: https://www.sas.com/en_us/software/platform.html,
https://www.sas.com/en_us/software/sas9.html

Record Creation Time: 20220129T080248+0000

Record Last Update: 20260801T042641+0000

Ratings and Alerts

No rating or validation information has been found for Statistical Analysis System.

No alerts have been found for Statistical Analysis System.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 7165 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Siegel F, et al. (2026) Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. *Cancer discovery*, 16(1), 81.

Rugo HS, et al. (2026) Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-Mutant Metastatic Breast Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(1), 179.

Huang MH, et al. (2026) Risk of Stroke in Patients With Schizophrenia, Bipolar Disorder, and Major Depressive Disorder: A Cohort Study of 183,504 Subjects. *Acta psychiatrica Scandinavica*, 153(1), 54.

Giurini L, et al. (2025) Lower Neighborhood-Level Socioeconomic Status Is Associated with Lower Colorectal Cancer Screening Uptake in the Southern Community Cohort Study. *Cancer prevention research (Philadelphia, Pa.)*, 18(6), 355.

Güller U, et al. (2025) Adjuvant Aspirin Treatment in PIK3CA-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(15), 3142.

Min S, et al. (2025) Iron Consumption and Colorectal Cancer in Korean Adults: A Prospective Cohort Study. *Nutrients*, 17(8).

Weintraub D, et al. (2025) Use of Robust Norming to Create a Sensitive Cognitive Summary Score in De Novo Parkinson's Disease: An Illustrative Example. *Movement disorders : official journal of the Movement Disorder Society*, 40(3), 468.

Parikh RR, et al. (2025) Associations Between Cancer and Atrial Fibrillation: The Atherosclerosis Risk in Communities Study. *Mayo Clinic proceedings. Innovations, quality & outcomes*, 9(4), 100634.

Zhang N, et al. (2025) Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(15), 3194.

Albayyaa M, et al. (2025) Hormonal Therapy Patterns in Older Men with Prostate Cancer in the United States, 2010-2019. *Cancers*, 17(19).

Fan L, et al. (2025) Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2- breast cancer: The LINUXtrial. *Cancer cell*.

Koric A, et al. (2025) Race-related subsequent breast events after ductal carcinoma in situ: A Surveillance, Epidemiology, and End Results-based analysis. *Cancer*, 131(22), e70164.

Tsimberidou AM, et al. (2025) Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(6), 965.

Carneiro BA, et al. (2025) Safety and Efficacy of Copanlisib in Combination with Nivolumab: A Phase Ib Study in Patients with Advanced Solid Tumors. *Cancer research communications*, 5(3), 444.

Li H, et al. (2025) IBI310 plus sintilimab vs. placebo plus sintilimab in recurrent/metastatic cervical cancer: A double-blind, randomized controlled trial. *Med (New York, N.Y.)*, 6(5), 100573.

Takemoto K, et al. (2025) DGK γ Enhances Tumorigenic Activity in Bladder Cancer Patients With Chronic Kidney Disease. *Cancer medicine*, 14(5), e70710.

Hu L, et al. (2025) HMPL-306 in relapsed or refractory IDH1- and/or IDH2-mutated acute myeloid leukemia: A phase 1 study. *Med (New York, N.Y.)*, 6(6), 100575.

Simuni T, et al. (2025) Neuronal α -Synuclein Disease Stage Progression over 5 Years. *Movement disorders : official journal of the Movement Disorder Society*, 40(7), 1318.

Ziller SG, et al. (2025) Dual-energy X-ray absorptiometry derived adiposity and colorectal cancer incidence and mortality in postmenopausal women. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*.

Cifuentes L, et al. (2025) Genetic and physiological insights into satiation variability predict responses to obesity treatment. *Cell metabolism*, 37(8), 1655.